One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The original renal band is printed as >51-80 and the reduced dose as 950 mg/m2. These values are preserved as source text, not recalculated or silently corrected.
At eGFR 45-59 mL/min/1.73 m2, metastatic colorectal protocol 94 considers a 25% reduction or an alternative, whereas post-neoadjuvant breast protocol 3503 permits full dose with increased adverse-event risk. Protocol 94 explicitly identifies a committee-endorsed departure from ADDIKD.
What to reconcile: Choose by the exact cancer setting and protocol, not whichever dose is larger or smaller. These are two protocols from one organization, not independent confirmation. Record the indication, protocol number, renal metric and oncology rationale.
Open this note and its source referencesThe newly imported RX label specifies Cockcroft-Gault CrCl; the eviQ tables use indexed eGFR. Similar numbers do not establish equivalent renal categories. The newer RX text says a dose below CrCl 30 is not established, unlike the older preserved source restriction.
What to reconcile: Read the original and newer source in full. Do not convert a missing established dose into permission to use a regimen or substitute eGFR for CrCl without reconciling the method. A retrieval date alone does not establish a label version.
Open this note and its source referencesThe retrieved 2026 official labels state that a dosage below Cockcroft-Gault CrCl 30 is not established, whereas the older generic RX mirror calls this range contraindicated. Current labels also include pretreatment DPYD testing precautions.
What to reconcile: Use the exact current product label and oncology protocol; do not interpret absence of an established dose as permission. Older eviQ comparisons were not rechecked in this pass.
Open this note and its source referencesThis generic-tablet mirror states that severe impairment below Cockcroft-Gault CrCl 30 mL/min is a contraindication. Its dose section uses a 25% starting-dose reduction at CrCl 30-50. This is retained as source-specific wording, not silently substituted for current selected official labeling.
The separately retrieved 2026 official labels say a dose below 30 has not been established. These statements must remain attributed rather than averaged or converted into an invented severe-renal regimen.
RDM57-rxlist-capecitabine-64ae450f60-C1 · Source locator: Dose adjustments in special populations; Contraindications: Severe Renal Impairment
Selected sections only; not a complete prescribing monograph or independent clinician approval.
The hosted label mirror is not independent corroboration of its underlying label. Official-label confirmation of this new card remains pending unless a separate official card is shown.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=capecitabine&s1=RDM57-rxlist-capecitabine-64ae450f60&h1=8e3cee444991604ed4a4c10ca3570c854f642c68a7a7d346f42daf8a84ea1152